



3 March 2022

Issue of New Shares

NEW YORK and SYDNEY, Australia, March 3, 2022 - Beroni Group (OTCQX: BNIGF; NSX: BTG) ("Beroni" or the "Company"), advises that the Company has issued 20,000 ordinary shares to a service provider in lieu of cash.

Notice pursuant to Section 708A(5)(e) of the Corporations Act 2001

The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) that:

1. The Company on 2 March 2022 has issued 20,000 Shares in lieu of cash payment for services.
2. The Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act;
3. The Company is providing this notice under section 708A(5)(e) of the Corporations Act;
4. As at the date of this notice, the Company has complied with:
 - a. The provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. Section 674 of the Corporations Act; and
5. As at the date of this notice, other than as disclosed above, there is no information to be disclosed which is excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

-End-

About Beroni Group Limited

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA / CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.

Phone: +61 2 9159 1827

Email: enquiry@beronigroup.com

Website: www.beronigroup.com